JP2018515088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515088A5 JP2018515088A5 JP2017557346A JP2017557346A JP2018515088A5 JP 2018515088 A5 JP2018515088 A5 JP 2018515088A5 JP 2017557346 A JP2017557346 A JP 2017557346A JP 2017557346 A JP2017557346 A JP 2017557346A JP 2018515088 A5 JP2018515088 A5 JP 2018515088A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- amino acid
- insulin
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 150000001413 amino acids Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004877 Insulin Human genes 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 8
- 239000000710 homodimer Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940079288 Insulin receptor agonist Drugs 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 2
- 239000000859 incretin Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical group ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 101500025353 Homo sapiens Insulin A chain Proteins 0.000 claims 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158079P | 2015-05-07 | 2015-05-07 | |
| US62/158,079 | 2015-05-07 | ||
| PCT/US2016/029807 WO2016178905A1 (en) | 2015-05-07 | 2016-04-28 | Fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515088A JP2018515088A (ja) | 2018-06-14 |
| JP2018515088A5 true JP2018515088A5 (enExample) | 2018-08-23 |
| JP6591562B2 JP6591562B2 (ja) | 2019-10-16 |
Family
ID=55953435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557346A Active JP6591562B2 (ja) | 2015-05-07 | 2016-04-28 | 融合タンパク質 |
Country Status (40)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193380A1 (en) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
| RU2719856C1 (ru) | 2016-07-27 | 2020-04-23 | Хьюлетт-Паккард Дивелопмент Компани, Л.П. | Горизонтальный интерфейс для картриджа с запасом текучей среды, имеющего цифровой датчик уровня текучей среды |
| LT3551209T (lt) * | 2016-12-09 | 2021-09-10 | Akston Biosciences Corporation | Insulino-fc suliejimai ir panaudojimo būdai |
| TR201703622A1 (tr) * | 2017-03-09 | 2018-09-21 | Univ Yeditepe | Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün |
| EP3606560A2 (en) * | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
| HRP20221448T1 (hr) * | 2018-01-26 | 2023-01-20 | F. Hoffmann - La Roche Ag | Il-22 fc pripravci i postupci njihove primjene |
| KR20210025522A (ko) | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| US11267862B2 (en) * | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3655006B1 (en) | 2018-06-29 | 2021-11-17 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| CN112839681A (zh) | 2018-10-10 | 2021-05-25 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物及其医学用途 |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| WO2020190591A1 (en) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TW202434620A (zh) * | 2019-07-31 | 2024-09-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CA3154522A1 (en) | 2019-10-15 | 2021-04-22 | Christopher Carl Frye | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| HUE064376T2 (hu) * | 2019-12-19 | 2024-03-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP4121449A2 (en) | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor beta (il-2rb) binding polypeptides |
| WO2021207207A2 (en) | 2020-04-07 | 2021-10-14 | Neoleukin Therapeutics, Inc. | De novo protein decoys of angiotensin-converting enzyme 2 (ace2) |
| SI3972987T1 (sl) | 2020-04-10 | 2023-10-30 | Akston Biosciences Corporation | Antigen-specifična imunoterapija za covid-19 fuzijske proteine in postopki za uporabo |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US20230272030A1 (en) * | 2020-07-24 | 2023-08-31 | Jiangsu Gensciences Inc. | Insulin-fc fusion protein and application thereof |
| IL301926A (en) * | 2020-11-06 | 2023-06-01 | Amgen Inc | Antigen binding domain with reduced clipping rate |
| JP2024502720A (ja) * | 2020-12-14 | 2024-01-23 | イーライ リリー アンド カンパニー | 糖尿病を治療する方法 |
| WO2023004406A2 (en) | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| WO2023044318A2 (en) | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| TWI871539B (zh) | 2021-11-15 | 2025-02-01 | 美商美國禮來大藥廠 | 可保存之調配物 |
| JP2025509433A (ja) * | 2022-03-16 | 2025-04-11 | 北京拓界生物医薬科技有限公司 | ヒトインスリン類似体、その融合タンパク質及び医薬的使用 |
| US12139502B2 (en) | 2022-05-18 | 2024-11-12 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| EP4543909A1 (en) | 2022-06-23 | 2025-04-30 | Sanofi | Single chain insulins and fc conjugates thereof |
| WO2024137820A1 (en) * | 2022-12-20 | 2024-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Insulin receptor antagonist |
| CN115894720B (zh) * | 2023-01-16 | 2024-07-09 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
| CN121100383A (zh) | 2023-05-03 | 2025-12-09 | 伊莱利利公司 | 用于管理糖尿病的方法和系统 |
| WO2025059010A1 (en) | 2023-09-11 | 2025-03-20 | Eli Lilly And Company | Methods and systems for managing diabetes |
| WO2025061146A1 (zh) * | 2023-09-20 | 2025-03-27 | 上海迈晋生物医药科技有限公司 | 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途 |
| WO2025080923A1 (en) | 2023-10-13 | 2025-04-17 | Eli Lilly And Company | Insulin-fc fusion proteins |
| US12454565B2 (en) | 2024-03-21 | 2025-10-28 | Akston Biosciences Corporation | PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| AU2004251145C1 (en) * | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| WO2005040926A2 (en) | 2003-10-02 | 2005-05-06 | Carl Zeiss Smt Ag | Optical subassembly and projection objective for semiconductor lithography |
| ATE517119T1 (de) | 2003-12-03 | 2011-08-15 | Novo Nordisk As | Einzelketteninsulin |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| JP2009527526A (ja) | 2006-02-21 | 2009-07-30 | ノボ・ノルデイスク・エー/エス | 単鎖インスリンのアナログとその製薬的製剤 |
| EP1996709A2 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| EP1996223A1 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| EP2074141B1 (en) | 2006-09-22 | 2016-08-10 | Novo Nordisk A/S | Protease resistant insulin analogues |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| EP3173484B1 (en) * | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| US20100196405A1 (en) | 2007-07-10 | 2010-08-05 | Kingman Ng | GLP-1 Fc FUSION PROTEIN FORMULATION |
| CN101970477B (zh) | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| PT2910570T (pt) * | 2008-03-18 | 2017-01-24 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| RU2010147076A (ru) | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
| GB0812019D0 (en) | 2008-07-02 | 2008-08-06 | Asterion Ltd | Insulin |
| PE20110221A1 (es) | 2008-07-23 | 2011-04-06 | Hanmi Science Co Ltd | Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| CN103068842B (zh) | 2010-06-16 | 2016-10-19 | 印第安纳大学研究及科技有限公司 | 对胰岛素受体具有高活性的单链胰岛素激动剂 |
| WO2012109429A2 (en) | 2011-02-09 | 2012-08-16 | Glaxosmithkline Llc | Lyophilized formulations |
| CN102718870B (zh) * | 2011-05-24 | 2014-04-30 | 马鞍山中美德康生物科技有限公司 | 一种胰岛素生物增敏剂及其应用 |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| CN102516393B (zh) * | 2011-11-30 | 2017-03-15 | 北京康明百奥新药研发有限公司 | 胰岛素模拟肽融合蛋白和突变体及其应用 |
| CN103509118B (zh) * | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| CN104981251B (zh) | 2012-09-26 | 2018-03-20 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| CN105008395B (zh) | 2012-11-05 | 2020-12-29 | 卡斯西部储备大学 | 长效单链胰岛素类似物 |
| WO2014133327A1 (ko) | 2013-02-26 | 2014-09-04 | 한미약품 주식회사 | 인슐린 위치 특이적 결합체 |
| KR20150127596A (ko) * | 2013-03-14 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | 아펠린 융합 단백질 및 이들의 용도 |
| PT3055325T (pt) | 2013-10-07 | 2018-04-06 | Novo Nordisk As | Novo derivado de um análogo de insulina |
| CN116987172A (zh) | 2014-01-20 | 2023-11-03 | 韩美药品株式会社 | 长效胰岛素及其用途 |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
| KR20160001391A (ko) | 2014-06-27 | 2016-01-06 | 한미약품 주식회사 | 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도 |
| KR20160007295A (ko) | 2014-07-11 | 2016-01-20 | 한미약품 주식회사 | 인슐린 아날로그 |
| KR102569743B1 (ko) | 2014-10-06 | 2023-08-23 | 케이스 웨스턴 리저브 유니버시티 | 이상 단일 사슬 인슐린 유사체 |
| JP6484337B2 (ja) | 2014-11-21 | 2019-03-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | インスリン受容体部分アゴニスト |
| CN107810202A (zh) | 2015-02-17 | 2018-03-16 | 韩美药品株式会社 | 长效胰岛素或胰岛素类似物复合物 |
| CN110134210A (zh) | 2019-04-16 | 2019-08-16 | 深圳市国鑫恒宇科技有限公司 | 一种服务器一体机的温度控制方法、系统、装置及存储介质 |
-
2016
- 2016-04-20 AR ARP160101082A patent/AR105616A1/es unknown
- 2016-04-21 JO JOP/2016/0076A patent/JO3658B1/ar active
- 2016-04-22 TW TW105112730A patent/TWI656132B/zh active
- 2016-04-28 CN CN201680023998.4A patent/CN107531806B/zh active Active
- 2016-04-28 MD MDE20180255T patent/MD3292141T2/ro unknown
- 2016-04-28 HR HRP20200503TT patent/HRP20200503T1/hr unknown
- 2016-04-28 US US15/140,519 patent/US9855318B2/en active Active
- 2016-04-28 UA UAA201710105A patent/UA122146C2/uk unknown
- 2016-04-28 PT PT167216050T patent/PT3292141T/pt unknown
- 2016-04-28 SI SI201630651T patent/SI3292141T1/sl unknown
- 2016-04-28 MY MYPI2017704174A patent/MY183025A/en unknown
- 2016-04-28 MX MX2017014284A patent/MX388594B/es unknown
- 2016-04-28 TN TNP/2018/000059A patent/TN2018000059A1/en unknown
- 2016-04-28 MA MA42037A patent/MA42037B1/fr unknown
- 2016-04-28 KR KR1020177031825A patent/KR102059736B1/ko active Active
- 2016-04-28 PE PE2017002375A patent/PE20180507A1/es unknown
- 2016-04-28 NZ NZ736470A patent/NZ736470A/en unknown
- 2016-04-28 WO PCT/US2016/029807 patent/WO2016178905A1/en not_active Ceased
- 2016-04-28 RS RS20200326A patent/RS60044B1/sr unknown
- 2016-04-28 EP EP16721605.0A patent/EP3292141B1/en active Active
- 2016-04-28 LT LTEP16721605.0T patent/LT3292141T/lt unknown
- 2016-04-28 PL PL16721605T patent/PL3292141T3/pl unknown
- 2016-04-28 ES ES16721605T patent/ES2799099T3/es active Active
- 2016-04-28 AU AU2016257659A patent/AU2016257659B2/en active Active
- 2016-04-28 EA EA201792199A patent/EA039770B1/ru unknown
- 2016-04-28 SG SG11201708194WA patent/SG11201708194WA/en unknown
- 2016-04-28 ME MEP-2020-51A patent/ME03709B/me unknown
- 2016-04-28 DK DK16721605.0T patent/DK3292141T3/da active
- 2016-04-28 CA CA2981102A patent/CA2981102A1/en active Pending
- 2016-04-28 JP JP2017557346A patent/JP6591562B2/ja active Active
- 2016-04-28 CR CR20170469A patent/CR20170469A/es unknown
-
2017
- 2017-09-19 ZA ZA2017/06334A patent/ZA201706334B/en unknown
- 2017-10-10 IL IL254965A patent/IL254965B/en active IP Right Grant
- 2017-10-17 SV SV2017005548A patent/SV2017005548A/es unknown
- 2017-10-31 CL CL2017002761A patent/CL2017002761A1/es unknown
- 2017-11-02 CO CONC2017/0011301A patent/CO2017011301A2/es unknown
- 2017-11-02 DO DO2017000258A patent/DOP2017000258A/es unknown
- 2017-11-06 EC ECIEPI201773650A patent/ECSP17073650A/es unknown
- 2017-11-07 PH PH12017502025A patent/PH12017502025B1/en unknown
- 2017-11-22 US US15/820,608 patent/US10709766B2/en active Active
-
2020
- 2020-03-16 CY CY20201100239T patent/CY1122929T1/el unknown
- 2020-06-05 US US16/893,498 patent/US11253574B2/en active Active
-
2022
- 2022-01-18 US US17/577,932 patent/US12059452B2/en active Active
-
2024
- 2024-06-27 US US18/756,062 patent/US20250032588A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515088A5 (enExample) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| JP2014524908A5 (enExample) | ||
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP2016512213A5 (enExample) | ||
| Bourgault et al. | Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide | |
| JP2014525901A5 (enExample) | ||
| AU2015255834B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2017538395A5 (enExample) | ||
| Tan et al. | Recent advances in half-life extension strategies for therapeutic peptides and proteins | |
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| JP2019507589A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| RU2019122785A (ru) | Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности | |
| JP2007001987A5 (enExample) | ||
| TW201716431A (zh) | 升糖素及glp-1共激動劑化合物 | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2013515057A5 (enExample) | ||
| JP2015502336A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2013501818A5 (enExample) | ||
| JP2017536337A5 (enExample) | ||
| HRP20180012T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2015504052A5 (enExample) |